The potential of targeting ribosome biogenesis in high-grade serous ovarian cancer

Shunfei Yan, Daniel Frank, Jinbae Son, Katherine M Hannan, Ross D. Hannan, Keefe T Chan, Richard B. Pearson, Elaine Sanij

Research output: Contribution to journalReview ArticleResearchpeer-review

13 Citations (Scopus)

Abstract

Overall survival for patients with ovarian cancer (OC) has shown little improvement for decades meaning new therapeutic options are critical. OC comprises multiple histological subtypes, of which the most common and aggressive subtype is high-grade serous ovarian cancer (HGSOC). HGSOC is characterized by genomic structural variations with relatively few recurrent somatic mutations or dominantly acting oncogenes that can be targeted for the development of novel therapies. However, deregulation of pathways controlling homologous recombination (HR) and ribosome biogenesis has been observed in a high proportion of HGSOC, raising the possibility that targeting these basic cellular processes may provide improved patient outcomes. The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib has been approved to treat women with defects in HR due to germline BRCA mutations. Recent evidence demonstrated the efficacy of targeting ribosome biogenesis with the specific inhibitor of ribosomal RNA synthesis, CX-5461 in v-myc avian myelocytomatosis viral oncogene homolog (MYC)-driven haematological and prostate cancers. CX-5461 has now progressed to a phase I clinical trial in patients with haematological malignancies and phase I/II trial in breast cancer. Here we review the currently available targeted therapies for HGSOC and discuss the potential of targeting ribosome biogenesis as a novel therapeutic approach against HGSOC.

Original languageEnglish
Article number210
Number of pages17
JournalInternational Journal of Molecular Sciences
Volume18
Issue number1
DOIs
Publication statusPublished - 20 Jan 2017

Keywords

  • CX-5461
  • High-grade serous carcinoma
  • Homologous recombination
  • Pol I
  • Ribosome biogenesis

Cite this